German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Merck now expects mid-term annual organic sales growth in the low- to mid single-digit percentage range for its healthcare business, having guided for “slight growth” last year. It expects mid-to-high single-digit percentage growth for Life Science, … [707 chars]
Source: Reuters | Published: 2025-10-16T05:04:48Z
Credit: Reuters
